期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

代谢组学技术在帕金森病中的研究进展 被引量：1

Metabolomics technology in parkinson's disease research
下载PDF
导出
摘要 目前代谢组学技术在疾病治疗中的研究与应用正处于探索阶段,随着现代分析技术的迅猛发展,代谢组学在各类疾病诊断与治疗中已取得突破性的进展。本研究在参考国内外大量相关文献的基础上,从代谢组学技术与帕金森病特点两个方面进行分析,提出将代谢组学技术引入帕金森病的研究中可为该疾病的早期诊断和合理治疗提供更科学有效的方案,有望全面系统地揭示帕金森病的科学内涵。 Current metabolomics technologies in the treatment of diseases research and application are in the exploratory stage,with the rapid development of modern analytical techniques,metabolomics in the diagnosis and treatment of various diseases has made a breakthrough.In this study,a large number of relevant literature on domestic and international basis,from metabolomics technology and characteristics of two aspects of Parkinson＇s disease analysis,the metabolomics technology into the study of Parkinson＇s disease for that early diagnosis and reasonable to provide more scientific and effective treatment programs,is expected to reveal a comprehensive and systematic scientific connotation of Parkinson＇s disease.
作者 张士森
机构地区 山东省宁津县人民医院神经内科
出处 《中国医药科学》 2013年第14期31-33,共3页 China Medicine And Pharmacy
关键词 帕金森病 代谢组学 诊断 治疗 Parkinson＇s disease Metabolomics Diagnosis Treatment
分类号 R741 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献2

二级参考文献51

  • 1Hellmold H, Nilsson CB, Schuppe-Koistinen I et al. Identification of end points relevant to detection of potentially adverse drug reactions. Toxicology Letters, 2002, 127:239.
  • 2Aranbar N, Singh BK, Stockton GW et al. Automated mode-of-Action detection by metabolic profiling. Biochem Biophys Res Commun, 2001, 286: 150- 155.
  • 3Fell DA. Beyond genomics. Trends Genet, 2001,17 : 680 - 682.
  • 4Fairlamb AH. Brave new world of post-genomics ! Trends Parasitol,2003,17:255 - 256.
  • 5Oliver DJ, Nikolau B, Wurtele ES. Functional genomics: high-throughput mRNA, protein, and metabolite analyses. Metabolic Engineering, 2002, 4: 98-106.
  • 6Smith LL. Key challenges for toxicologists in the 21st century .Trends Pharmacol Sci, 2001, 22:281 - 285.
  • 7Stafford DE, Stephanopoulos G. Metabolic engineering as an integrating platform for strain development. Ecology amt Industrial Microbiology, 2003. 336- 340.
  • 8Harrigan G. Metabolic profiling: pathways in drug discovery. Drug Discovery Today, 2003, 7: 351- 352.
  • 9Schwab W. Metabolome diversity: too few genes, too many metabolites? Phytochemistry, 2003, 62: 837- 849.
  • 10Wood NT. Profiling modified metabolomes. TRENDS in Plant Science, 2003, 6:191.

共引文献73

同被引文献10

  • 1Cui Y, Liu X, Wang M, et al. Lysophosphatidylcholine and amide as metabolites for detecting alzheimer disease using ultrahigh-performance liquid chromatography- quadrupole time-of-flight mass spectrometry-based metabonomics[J]. J Neuropathol Exp Neurol,2014,73(10): 954-963.
  • 2Mancuso C, Bates TE, Butterfield DA, et al. Natural an- tioxidants in Alzheimer's disease[J]. Expert Opin Investig Drugs,2007,16(12): 1921-1931.
  • 3Revett TJ, Baker GB, Jhamandas J, et al. Glutamate sys- tem, amyloid 13 peptides and tau protein: functional in- terrelationships and relevance to Alzheimer disease pathology[J]. J Psychiatry Neurosci,2013,38(1):6-23.
  • 4Peng J, Guo K, Xia J, et al. Development of isotope la- beling liquid chromatography mass spectrometry for mouse urine metabolomics: quantitative metabolomic study of transgenic mice related to Alzheimer's disease [J]. J Proteome Res,2014,13(10):4457-4469.
  • 5Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases [J]. Neurobiol Dis,2009,35(2):165-176.
  • 6Luan H, Liu LF, Meng N, et al. LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease[J]. J Proteome Res,2015,14(1):467-478.
  • 7Beneduci A, Cuccurullo M, Pontoni G, et al. Perspectives of 1H-NMR-based urinary metabonomics in Fabry di- sease[J]. J Nephrol,2010,23(Suppl 16):$213-$220.
  • 8Auray-Blais C, Boutin M, Gagnon R, et al. Urinary globo- triaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics[J]. Anal Chem,2012,84(6):2745- 2753.
  • 9Schiffmann R, Waldek S, Benigni A, et al. Biomarkers of Fabry disease nephropathy[J]. Clin J Am Soc Nephrol, 2010,5(2):360-364.
  • 10Shima N, Miyawaki I, Bando K, et al. Influences of methamphetamine-induced acute intoxication on urinary and plasma metabolic profiles in the rat[J]. Toxicology, 2011,287(1-3):29-37.

引证文献1

二级引证文献2

中国医药科学
2013年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部